What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Betaseron
97%DGNews: Betaseron Administered in a Needle-Free System for Multiple Sclerosis
97%DGNews: Two Innovative Reimbursement Approaches Introduced for Betaseron Patients
96%DGNews: FDA Approves Betaseron(R) (Interferon beta-1b) for Use After the First Event Suggestive of Multiple Sclerosis
96%DGNews: FDA Approves Betaseron(R) (Interferon beta-1b) for Use After the First Event Suggestive of Multiple Sclerosis
96%DGNews: New Autoinjection Device Designed to Work With Interferon beta-1b Now Available for Patients With Multiple Sclerosis
96%DGNews: Quebec Government to Reimburse Betaseron for Multiple Sclerosis
95%DGNews: Betaseron (Interferon Beta-1b) Gains Expanded FDA Labeling Approval for Treating Relapsing Forms of Multiple Sclerosis
95%DGNews: Room-Temperature Betaseron Available Nationwide
95%DGNews: European Committee Recommends Betaseron For Secondary Progressive MS
95%DGNews: AAN: Betaseron (interferon beta-1b) therapy delays axonal damage in secondary progressive multiple sclerosis
95%DGNews: Quebec Government's Decision to Reimburse Betaseron Applauded
95%DGNews: U.S. Secondary-Progressive MS Betaseron Study Stopped Early
95%DGNews: Kaiser Permanente and National MS Society Join Forces in Clinical Trial Study
94%DGNews: Multiple Sclerosis Drug Avonex (Interferon Beta-1a) As Effective As Betaseron (Interferon Beta-1b) With Fewer Side Effects
94%DGNews: Betaseron Fast Tracked In Canada For Multiple Sclerosis
93%DGNews: FDA Approves Room-Temperature Formulation of Betaseron (Interferon Beta-1b) for Multiple Sclerosis
93%DGNews: Copaxone (Glatiramer acetate) and Betaseron® (Interferon beta-1b) Yield Statistically Significant Results In Relapsing-Remitting Multiple Sclerosis
93%DGNews: Betaseron Approved In Europe For Secondary-Progressive MS
91%DGNews: Glatiramer Acetate Injections Reduced Relapses by 75% in Both Treatment-Naïve Multiple Sclerosis Patients and Those Failing Interferon Beta-1b
91%DGNews: ECTRIMS/ACTRIMS: Betaferon/Betaseron (Interferon beta 1b) Demonstrates Treatment Effect in Patients with Primary Progressive Multiple Sclerosis
91%DGNews: ANA: Copaxone, Betaseron Effective But No Statistically Significant Effect for Avonex
90%DGNews: Interferon Beta-1b Improvements in Multiple-Sclerosis Patients Maintained Over the Long Term: Presented at AAN
89%DGNews: Early Interferon Beta-1b Use in Multiple Sclerosis Patients Slows Disability Onset: Presented at AAN
89%DGNews: Clinical Effects of Copaxone (Glatiramer) or Interferon Therapy Compared to Untreated Patients with Relapsing-Remitting Multiple Sclerosis
88%DGNews: Treatment of Multiple Sclerosis at the First Demyelinating Event Delays Progression: Presented at ANA
88%DGNews: Early Interferon Beta-1b Treatment Thwarts Multiple-Sclerosis Progression: Presented at AAN
88%DGNews: Caremark Announces a Disease Management Program for MS
87%DGNews: Betaferon(R) (Interferon beta-1b) Approved in Canada for Treatment of the Earliest Stages of Multiple Sclerosis
85%DGNews: Interferon Beta-1b (Extavia) Approved in European Union for Treatment of Multiple Sclerosis
85%DGNews: Betaferon Causes Less Injection Site Pain and Injection Site Reactions Than Rebif in Patients With Multiple Sclerosis: Presented at ECTRIMS
85%DGNews: Once-Weekly Avonex Shows Better Patient Compliance Than Other MS Treatments
85%DGNews: Interferon-Beta-1b Appears More Effective in Preventing Multiple Sclerosis Relapse than Interferon Beta-1a
84%DGNews: Magnetic Resonance Imaging Can Predict Who Will Develop Multiple Sclerosis: Presented at WCTRMS
84%DGNews: Not all Interferon-beta Treatments are Created Equal in Developing Neutralizing Antibodies
84%DGNews: ANA: Interferon Treatment May Stabilize Multiple Sclerosis Progression As Well As Reduce Attacks
83%DGNews: 16-Year Follow-Up Data for Interferon Beta-1b Show Positive Impact on Course of Multiple Sclerosis and Mortality: Presented at ECTRIMS
83%DGNews: Trial Shows Risk of Developing Multiple Sclerosis Significantly Reduced with Interferon Beta-1b Early Treatment
83%DGNews: BENEFIT Study Shows Interferon Beta-1b Delays Development of MS in Patients with First Clinical Signs of Disease
82%DGNews: Betaferon (Interferon Beta-1b) Approved in Europe as a First-Line Treatment for the Earliest Stages of Multiple Sclerosis
82%DGNews: Three Recent Independent Publications Confirm that Neutralizing Antibodies Matter in Multiple Sclerosis
82%DGNews: FDA Proposes New Use Initiative
82%DGNews: MS Society Recommends Early Drug Therapy
81%DGNews: No Differences Found Between Interferon Beta-1b and Glatiramer for Multiple Sclerosis: Presented at ECTRIMS
81%DGNews: AAN: No Differences Seen in Interferon Beta Products in QUASIMS Study
80%DGNews: MS Patients Not Getting Drugs to Slow Disease Progression, Research Shows
80%DGNews: Study Confirms Benefits of High-Dose, High-Frequency Beta Interferon Regimen in Treatment for Multiple Sclerosis
80%DGNews: AAN: Double-Drug Therapy, Mitoxantrone/Interferon beta-1b, Shows Benefit in Multiple Sclerosis
77%DGNews: Interferon Beta-1b Promising in Delaying Progression for Patients at Very Beginning of Multiple Sclerosis: Presented at EFNS
76%DGNews: Early, High-Dose Rebif (Interferon Beta-1a) Slows MS Progression
75%DGNews: REVISED: Glatiramer Acetate Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When interferon beta-1a Failed
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.